Pfizer PFE is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being its upcoming loss of exclusivity (“LOE”) cliff. Though Pfizer ...

Pfizer Inc. will pay $4.9 billion for the obesity startup Metsera Inc. in a bid to catch up to rival drugmakers after failing to compete with its own weight-loss medications. The US drugmaker agreed ...

Pfizer has launched a two-pronged litigation effort to stop Novo Nordisk from acquiring a weight loss drug company, filing a breach of contract suit in the Court of Chancery on Friday and an antitrust ...

President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices across Pfizer drugs, according to the Wall Street Journal. Trump ...

Pfizer's (NYSE:PFE) entry into the obesity treatment market through its $4.9B deal to acquire Metsera (NASDAQ:MTSR) is the latest indication that Big Pharma wants a piece of the weight loss drugs pie ...

Pfizer is acquiring Metsera, a clinical-stage biopharmaceutical company with a focus on medicines for obesity and cardiometabolic diseases, in a deal valued at up to $7.3 billion. “Pfizer said it ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

President Donald Trump speaks in the Oval Office of the White House, Tuesday, Sept. 30, 2025, in Washington. (AP Photo/Alex Brandon) WASHINGTON (AP) — Pfizer has agreed to lower the cost of ...